Soleus Capital is a healthcare investment firm focused on the innovative areas of life sciences, including biotech, medtech, diagnostics, and genomics. Founded in 2018 and based in Greenwich, CT, the firm manages hedge, private equity, and credit funds primarily focused on healthcare-related companies across the United States.
52% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $115.8M (across 53 rounds with reported amounts).
Portfolio
45
Fund Size
—
Top Stage
Series C
Last 12 Mo
4
Team
SM
Steve Musumeci
Founding Partner
BL
Benjamin Lund
Partner
DC
David Canner
Partner
BW
Ben Wessner
Principal
CM
Connor McDermott
Analyst
RB
Ryan Berry
Biotech Investor
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
63 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| PParabilis | Series F | $305M | Sep 2026 |
| BBridge To Life | Series C | $110M | Aug 2026 |
| BBridge To Life | Bridge | — | Aug 2026 |
 Crystalys Therapeutics Inc | Series B | $130M | Jul 2026 |
 Parabilis Medicines | Series F | $305M | Jan 2026 |
| PParabilis | Series F | $305M | Jan 2026 |
 Crescent Biopharma | Growth | $200M | Jun 2025 |
 Pillar Biosciences | Series B | $34.5M | May 2025 |
 Neurona Therapeutics | Unknown | $102M | Apr 2025 |
 Abcuro, Inc. | Series C | $200M | Feb 2025 |
 Star Therapeutics | Series D | $125M | Jan 2025 |
 OrganOx | Unknown | $142M | Jan 2025 |
 Neurona | Series A | $102M | Jan 2025 |
| Pillar Biosciences | Series C | $64M | Jan 2025 |
 Blue Earth Therapeutics Ltd | Series A | $76.5M | Oct 2024 |
 Parse Biosciences | Series C | — | Dec 2023 |
 Beta Bionics | Series A | — | Sep 2023 |
 COMPASS Pathways | Series A | $285M | Aug 2023 |
| Parse Biosciences | Series C | $50M | Jan 2023 |
| Beta Bionics | Series C | $57M | Feb 2022 |
 RayzeBio | Series D | $160M | Jan 2022 |
 Freenome | Series D | $300M | Dec 2021 |
| AAntios Therapeutics, Inc. | Series B | $75M | Nov 2021 |
| AAntios Therapeutics, Inc. | Series A | $75M | Nov 2021 |
 Obsidian Therapeutics | Series B | $115M | Sep 2021 |
Page 1 of 3
Top Co-Investors
RA Capital Management22 shared
Cormorant Asset Management16 shared
Perceptive Advisors14 shared
HBM Healthcare Investments10 shared
Novo Holdings A/S9 shared
Pontifax9 shared
Logos Capital9 shared
Farallon Capital Management8 shared
Redmile Group8 shared
RTW Investments, LP7 shared
Sofinnova Partners7 shared
Samsara BioCapital7 shared
Foresite Capital7 shared
OrbiMed7 shared
Novo Capital7 shared
Adage Capital Management6 shared
CaaS Capital6 shared
Frazier Life Sciences6 shared
Sands Capital6 shared
Alexandria Venture Investments6 shared
Last updated: 20 October 2026